Skip to content

Use of Herbal Medicine likeTulasi,Amruth(Giloy), Turmeric,Ashwagandha as add on treatment in COVID-19 Patients

A clinical Study to Evaluate the Role of Herbal Immunomodulators as add on Treatment in Asymptomatic and Mildly Symptomatic COVID-19 Confirmed Cases.

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025592
Enrollment
50
Registered
2020-06-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Immunity Kit: Shakti drops: Dosage: 5 drops 3 times a day (Morning/ Afternoon/Night) Amruth tablet: Dosage: 1 tablet 2 times a day Turmeric plus tablet:: Dosage: 1 tablet 2 times a

Sponsors

Sri Sri Tattva
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Confirmed Asymptomatic and mildly symptomatic cases of COVID-19 infection by laboratory tests Age limit 18 to 60 years both Male and Female Uncomplicated cases of COVID - 19 patients on Allopathic medication Patients in whom ventilator support is not required Patients with no associated co morbidities Patients willing to give informed consent to participate in the clinical trial

Exclusion criteria

Exclusion criteria: COVID-19 positive patients above 60 years of age & below 18 years with Symptoms. Patients with associated comorbidities like hypertension, type 2 or type 1 diabetes mellitus, chronic or acute renal failure Patients on Immuno-suppression therapy Pregnant Women or lactating mothers Patients in advanced stage of disease requiring emergency medical intervention like pneumonia, bronchial asthma, organ failure

Design outcomes

Primary

MeasureTime frame
Early recovery in the signs and symptoms of cases of Asymptomatic and mild symptomatic COVID-19 patients by adding Ayurvedic medicines which are effective in enhancing immunity of body and reducing the symptoms such as Fever and respiratory distressTimepoint: Day 1 and Day 30

Secondary

MeasureTime frame
a. TNF-α b. IL-6 c. IFN- β d. IFN-λTimepoint: Day 1 and Day 30

Countries

India

Contacts

Public ContactDr M Ravi Kumar Reddy

Bangalore Medical College research Institute

bmccrj@gmail.com9448292424

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026